<DOC>
	<DOCNO>NCT00082628</DOCNO>
	<brief_summary>The primary objective study determine Serostim® 4 mg administer daily 12 week treatment abnormal fat accumulation distribution associate HIV-associated Adipose Redistribution Syndrome ( HARS ) reduce Visceral Adipose Tissue ( VAT , measure CT scan ) effectively placebo .</brief_summary>
	<brief_title>Treatment Abnormal Adipose Tissue Accumulation HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>1 . Have write laboratory documentation HIV infection one follow method : Detectable viral load measure polymerase chain reaction ( PCR ) amplification , branch chain DNA ( bDNA ) signal amplification presence p24 antigen . Presence HIV antibodies confirm either Western blot immunofluorescence assay . Written laboratory documentation HIV infection must obtain prior randomization . In absence document historical confirmation , assay HIV antibody include Screening Laboratory Panel . Results confirm Western Blot . 2 . Have evidence excess abdominal adipose deposition measure anthropometric methodology , use follow cut value : Men : Waist circumference &gt; 88.2 cm AND waist : hip ratio &gt; = 0.95 . Women : Waist circumference &gt; 75.3 cm AND waist : hip ratio &gt; = 0.9 . 3 . Are take antiretroviral medication ( ) ( ) approve ( ) available Treatment IND . The regimen must remain stable 30 day prior study entry . Subjects must also agree discontinue change regimen duration study except judge medically necessary . 4 . Have parameter value less follow limit ( use result central laboratory ) : AST , ALT , amylase &lt; = 3 time upper limit normal ( Screening ) . Fasting triglyceride &lt; = 1,000 mg/dL ( Screening ) . Fasting glucose &lt; 110 mg/dL ( Screening ) . Twohour ( 120 minute ) glucose &lt; 140 mg/dL ( Screening ) . 5 . Weight &gt; = 36 kg ( 79.3 lb ) 6 . Be 18 60 year age ( inclusive ) unless local law dictate different limit . 7 . Sufficiently literate English able comprehend complete Quality Life Questionnaire . 8 . Willing able comply protocol duration study . 9 . Have voluntarily provide write informed consent ( subject authorization HIPAA ) , prior perform studyrelated procedure part normal medical care , understand subject may withdraw consent time without prejudice future medical care . 10 . Female subject must : 1 . Be post menopausal ( &gt; = 1 year ) surgically sterilize ( i.e. , undergone tubal ligation hysterectomy ) 2 . Use contraceptive method duration study : Hormonal contraceptive Intra uterine device Diaphragm spermicide , condom spermicide . And 3 . Must neither pregnant breast feeding . 4 . Confirmation female subject childbearing potential pregnant must establish negative betahCG serum pregnancy test 14day screening period prior Study Day 1 . If betahCG serum pregnancy test perform 7 day prior Study Day 1 , urine pregnancy test must perform site laboratory Study Day 1 confirm negative test result . 1 . Have active AIDSdefining opportunistic complication ( OC ) define CDC untreated suspect serious systemic infection , persistent fever &gt; = 101°F ( 38.3°C ) 30 day prior study entry . 2 . Any active past history malignancy , except localize cutaneous Kaposi 's sarcoma ( few 10 lesion , none large 2 cm , active therapy ) . Such exception must confirm write Serono Study Director . 3 . Have CNS mass active CNS process associate neurological finding . 4 . Have unstable untreated hypertension , define &gt; = 140/90 mm Hg time Screening Visit , and/or initiate change antihypertensive therapy 30 day prior Study Day 1 . 5 . Have acute critical illness treat intensive care unit , e.g. , due complication follow open heart abdominal surgery , multiple accidental trauma , acute respiratory failure . 6 . Have recent history sleep apnea intermittent upper respiratory obstruction . 7 . Have condition , interfere informed consent protocol compliance include , limited , active substance abuse and/or dementia . 8 . Are unable comply Concomitant Therapy restriction include : therapy obesity include therapy anorexigenic fat reduce drug antidiabetic insulin sensitize medication systemic glucocorticoid systemic chemotherapy , interferon radiation therapy treatment androgenic agent include , limited testosterone , nandrolone , oxandrolone , oxymetholone , etc . ( testosterone replacement therapy hypogonadism exception exclusion allow start &gt; 30 day prior Study Day 1 ) progestational agent , unless use oral contraception postmenopausal hormone replacement therapy appetite stimulant investigational agent , unless approve advance study medical director . Specifically , experimental antiretroviral agent disallow , unless available treatment IND expand access program ( 30 day ) . Liposuction elective plastic surgery AIDS wasting therapy prior growth hormone treatment study drug ( 12 month prior screen visit ) 9 . Have ever diagnose follow condition : Pancreatitis Carpal tunnel syndrome ( unless resolve surgical release ) Diabetes mellitus Angina pectoris Coronary artery disease Any disorder associate moderate severe edema ( e.g. , ascites , nephrotic syndrome , congestive heart failure , lymphedema ) . 10 . Allergy hypersensitivity growth hormone . 11 . Are participate clinical study . In order participate trial subject must meet inclusion exclusion criterion specify . Requests protocol exceptions/exemptions must come participating , fully initiate site prospective patient consent undergo screening . Exceptions/exemptions allow Trial Director . There program place allow drug single patient IND , expand access protocol . This statement hold true child adult .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>growth hormone</keyword>
	<keyword>Serostim®</keyword>
	<keyword>Human Adipose Redistribution Syndrome</keyword>
	<keyword>Human Immunodeficiency Virus lipodystrophy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>